In this page you'll find talks from today's Plenary Sessions, just in case you missed them or want to revisit them. You can view the videos below, or see them all on Vimeo

Richard Hayes, Professor of Epidemiology and International Health, London School of Hygiene and Tropical Medicine, UK

In the opening plenary session of day 3 of the Conference, Professor Richard Hayes spoke about the future of prevention trials in HIV. The field of HIV prevention research has turned the corner over the past two years with a series of trials of different interventions showing some evidence of effect. These successes should re-energise the field but also bring their own challenges for future prevention trials. Professor Hayes talk explores some of these opportunities and challenges.

Accompanying slides will be available shortly

 

Joseph Romano, NWJ Group, USA

In the second plenary presentation of day 3 of the Conference, Joseph Romano spoke about new technology for HIV prevention. Although the HIV epidemic continues to devastate populations in many parts of the world, prevention technologies and strategies are being emboldened by recent outcomes in efficacy trials. Efficacy has been shown with both oral and topical prevention products in HIV- populationsm and test and treat strategies in were effective at preventing transmission from HIV+ individuals.

Accompanying slides will be available shortly

Third presenter:

Debrework Zewdie, Deputy Executive Director, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland

In the final plenary presentation of day 3 of the Conference, Debrework Zewdie spoke about global resourcing for new HIV prevention technology. Innovative HIV orevention technologies are urgently needed, making the prospect of a microbicide being commercially available and accessible to women and most at-risk populations in the coming years one of the most exciting HIV developments since antiretroviral therapy. This talk discusses the funding issues involved, and contributions of funding bodies to shape the market demand through encouraging countries to adopt and increase access to cost-effective HIV prevention technologies.